Drug-Resistant Malaria - libdoc.who.int - World Health Organization

More documents

Recommendations

Info

104 / APPENDICES Progress and planning report Thailand Review of the Regional Collaborative Studies on Drug-Resistant Plasmodium falciparum malaria. Analysis of answers to questionnaire. Dr L. MOLl NEAUX Predicting the westward spread of drugresistant falciparum malaria in Asia. Dr D.F. CLYDE A synthesis of the current situation of the drug response of P.falciparum in WPR including tentative explanation and projection. Dr W.J.O.M. van DIJK A synthesis of the current distribution of drug response of P.falciparum malaria in the American Region. Dr F.J. LOPEZ-ANTUNANO and Dr J.A. NAJERA-MORRONDO The role of population migration in the spread of drug-resistant falciparum strains. Dr S. PINICHPONGSE and Dr E .B. OOBERSTYN The role of population migration in the spread of drug-resistant falciparum strains. Dr Nyunt HLAING Chloroquine and mefloquine sensitivity testing in the field. Dr A.D. PARKINSON et al. Studies on drug-resistant P.falciparum with the in vitro and in vivo tests carried out on the same infections. Dr C. VALERA Technical aspects of interest noted during the studies on the response of P.falciparum to chloroquine in the Philippines, with the in vitro technique (macro test). Dr C. VALERA Application of the micro in vitro technique on the response of P.falciparum to antimalarial drugs in South-East Asia. Mr W. ROONEY MAL/DRUG/81/WP.lg ( SEARO) MAL/DRUG/81/WP.lh (SEARO) MAL/DRUG/81/WP.2(HQ) MAL/DRUG/81/WP.2 (SEARO) MAL/DRUG/81/WP.2 (WPRO) MAL/DRUG/81/WP.2 (AMRO) MAL/DRUG/81/WP.3 (SEARO) MAL/DRUG/81/WP.4 (SEARO) MAL/DRUG/81/WP.3 (WPRO) MAL/DRUG/81/WP.5 (WPRO) MAL/DRUG/81/WP.6 (WPRO) MAL/DRUG/81/WP.5 ( SEARO)
APPENDICES / 105 Comparative study on the m1cro in vitro and the in vivo tests on the response of p.falciparum to chloroquine in Burma. Dr Myint LWIN et al. Monitoring of drug response: tests, data processing and analysis, sampling. Dr L. MOLINEAUX and Mr D. PAYNE Development of drug sensitivity monitoring programmes: future needs and funding. Dr S. GORIUP Biological aspects related to drug resistant P.falciparum and its control. Dr W.H. WERNSDORFER Alternative drugs to be used against p.falciparum malaria; practical guidelines and suggestions. Professor R.E. DESJARDINS Alternative drugs to be used against multiresistant p.falciparum malaria with special reference to the present situation in Thailand. Professor T. HARlNASUTA Alternative drugs to be used against multi-resistant P.falciparum malaria, with special reference to drug combination comparative trials in Burma. Dr Franco TIN Control of transmission of drug-resistant P.falciparum with particular reference to the conta1nment programme in India. Dr A.P. RAY The effect of P.falciparum resistance on the application of the four tactical variants and suggestions to overcome expected implications. Dr G.A. FARID Policies on drug use aiming at preventing, delaying or reversing the selection of resistant P.falciparum parasites. Professor W. PETERS Field research on the control of transmission of drug-resistant P.falciparum. Professor G. JEFFERY MAL/DRUG/81/WP.6 (SEARO) MAL/DRUG/81/WP.3 (HQ) MAL/DRUG/8l/WP.4 (HQ) MAL/DRUG/81/WP.5 (HQ) MAL/DRUG/8l/WP.6 (HQ) MAL/DRUG/81/WP.7 (SEARO) MAL/DRUG/81/WP.8 (SEARO) MAL/DRUG/8l/WP.9 (SEARO) MAL/DRUG/8l/WP.7 (WPRO) MAL/DRUG/81/WP.8a (WPRO) MAL/DRUG/81/WP.7 (HQ)
Page 1:
Drug-Resistant Malaria The Report o
Page 5:
Foreword A meeting on drug-resistan
Page 8 and 9:
CONTENTS Page Drug Pressure and Res
Page 10 and 11:
2 / INTRODUCTION Differences in dru
Page 13 and 14:
II. Opening Address and Messages Ol
Page 15 and 16:
OPENING ADDRESS / 7 phical boundari
Page 17 and 18:
OPENING ADDRESS / 9 to preserve for
Page 19 and 20:
OPENING ADDRESS / 11 is also here a
Page 21 and 22:
Ill. Review of Drug Resistance in P
Page 23 and 24:
REVIEW I 15 Table 1. Sensitivity Te
Page 25 and 26:
REVIEW / 17 Other Studies Validatio
Page 27 and 28:
Distribution of Chloroquine-Resista
Page 29 and 30:
REVIEW I 21 are signs to suggest th
Page 31 and 32:
REVIEW / 23 (h) specialized investi
Page 33 and 34:
REVIEW / 25 TABLE 3~ Comparison of
Page 35 and 36:
REVIEW / 27 Of 22 mefloquine in vit
Page 37 and 38:
REVIEW / 29 operational conditions
Page 39 and 40:
REVIEW / 31 the possible influence
Page 41 and 42:
IV. Monitoring of Drug Response of
Page 43 and 44:
MONITORING / 35 during recent years
Page 45 and 46:
MONITORING / 37 India, Sri Lanka an
Page 47 and 48:
Table 4. Results of Micro In Vitro
Page 49 and 50:
MONITORING / 41 The superiority of
Page 51 and 52:
MONITORING / 43 input of the result
Page 53 and 54:
MONITORING / 45 table time 1ag and
Page 55 and 56:
Table 6. Probability of Detecting t
Page 57 and 58:
MONITORING / 49 prevalence = 10% an
Page 59:
MONITORING / 51 TDR. At the end of
Page 62 and 63: 54 / RESEARCH RESULTS characteristi
Page 64 and 65: 56 / RESEARCH RESULTS EXO-ERYTHROCY
Page 67 and 68: VI. Control of Drug-Resistant P. fa
Page 69 and 70: CONTROL / 61 DRUG USE AIMING AT PRE
Page 71 and 72: Table 7. Specific Actions for the C
Page 73 and 74: CONTROL / 65 Table 8. Drugs or Comb
Page 75 and 76: Table 9. Suggested Use of Antimalar
Page 77 and 78: Table 9. Suggested Use of Antimalar
Page 79 and 80: CONTROL / 71 Radical therapy of mic
Page 81 and 82: CONTROL / 73 Tanzania several years
Page 83 and 84: VII. Field and Laboratory Research
Page 85 and 86: RESEARCH FOR CONTROL / 77 In vivo a
Page 87 and 88: RESEARCH FOR CONTROL / 79 migrants
Page 89 and 90: RESEARCH FOR CONTROL / 81 and Phase
Page 91: RESEARCH FOR CONTROL / 83 (b) Metho
Page 94 and 95: 86 / RECOMMENDATIONS and sulfonamid
Page 96 and 97: 88 / RECOMMENDATIONS (xiii) Simple
Page 99 and 100: IX. Summary The Meeting on Drug-Res
Page 101 and 102: APPENDIX 1 List of Participants, Ob
Page 103 and 104: APPENDICES / 95 Sri Lanka Dr M.K. B
Page 105 and 106: APPENDICES / 97 Papua New Guinea Dr
Page 107 and 108: APPENDICES / 99 TEMPORARY ADVISERS
Page 109 and 110: APPENDICES / 101 Dr L.E. Molineaux
Page 111: APPENDIX 2 List of Documents A. WOR
Page 115 and 116: APPENDIX 3.1 I 107 RESPONSE OF Plas
Page 117: APPENDIX 3.2 / 109 RESPONSE OF P. F
Page 120 and 121: 112 / APPENDICES 0.25 0.50 0.75 1.0
Page 122 and 123: 114 / APPENDICES Chloroquine is eff
Page 124 and 125: 116 / APPENDICES 1.4 Sulfonamide pl
Page 126 and 127: 118 / Various tetracycline analogs
Page 128 and 129: 120 / APPENDICES A loading dose on
Page 130 and 131: 122 / APPENDICES The drug should be
Page 132 and 133: 124 / APPEND ICE S 2. INDICATIONS f
Page 134 and 135: 126 / APPENDICES they are already r
Page 136 and 137: 128 / APPENDICES 5.2 In suppressive
Page 138 and 139: 130 / APPENDICES Outline research p
Page 140 and 141: 132 / APPENDICES Long-term To preve
Page 143 and 144: APPENDIX 8 Considerations Related t
Page 145 and 146: APPENDICES / 137 4. Screening point
show all

Drug-Resistant Malaria - libdoc.who.int - World Health Organization

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?